Unmute MS: Recent Episodes
Novartis Pharmaceuticals UK
Unmute MS is a series of podcasts sponsored by Novartis Pharmaceuticals UK investigating the biggest questions in MS. This podcast interviews a range of guests from different specialities to unpick the latest insights and current thinking about the questions that are most wanted to be unmuted in the field of MS.
(November 2020 MUL20-E027x)
Unmute MS is a series of podcasts sponsored by Novartis Pharmaceuticals UK investigating the biggest questions in MS through talking to a range of leading experts across different sectors in the field. In this episode, Professor Paul Matthews, Head of the Department of Brain Sciences at Imperial College London, explores further about imaging, this time focussing on how the results of imaging scans can impact on clinical practice, how we may be able to identify early signs of progression, and what are the best ways to communicate the results of imaging to patients.103914 | UK | February 2021
Unmute MS is a series of podcasts sponsored by Novartis Pharmaceuticals UK investigating the biggest questions in MS through talking to a range of leading experts across different sectors in the field. In this episode, Dr Ronan Burke, Clinical Psychologist and lead for the mood pathway for people with MS at the National Hospital for Neurology and Neurosurgery, Queen Square, explores specific management for patients, how the services are set up to support patients and how the very complex and changing nature of MS means there is no “typical” presentation.
101790 | UK | December 2020
Unmute MS is a series of podcasts sponsored by Novartis Pharmaceuticals UK investigating the biggest questions in MS through talking to a range of leading experts across different sectors in the field. In this episode, Dr Agne Straukiene, a Consultant Neurologist at Torbay and South Devon NHS Foundation Trust explores the importance of health and well-being as part of a holistic management plan for people with MS, and how vital is the role of health and well-being to patient outcomes in MS.101789 | UK | November 2020
Unmute MS is a series of podcasts sponsored by Novartis Pharmaceuticals UK investigating the biggest questions in MS through talking to a range of leading experts across different sectors in the field. In this episode, Professor Paul
Matthews, Head of the Department of Brain Sciences at
Imperial College London, explores how imaging has advanced MS research
and the implications this has on clinical practice, and what can imaging tell us in MS?
101787 | UK | February 2021
Unmute MS is a series of podcasts sponsored by Novartis Pharmaceuticals UK investigating the biggest questions in MS through talking to a range of leading experts across different sectors in the field. In this episode, Dr Ronan Burke, Clinical
Psychologist and lead for the mood pathway for people with MS at the
National Hospital for Neurology and Neurosurgery, Queen Square, explores the key mental health symptoms in people with MS,
in particular talking around the need for patients to
continually adjust and how psychologists support people with MS.
101786 | UK | December 2020
Unmute MS is a series of podcasts sponsored by Novartis
Pharmaceuticals UK investigating the biggest questions in MS through talking
to a range of leading experts across different sectors in the field. Dr
Wallace Brownlee, an MS Specialist Neurologist and MS Lead at the National
Hospital for Neurology and Neurosurgery, joins us again to continue the
conversation around SPMS. This episode focuses on the complexities of managing
patients with SPMS, particularly around the time of diagnosis and the
important roles of the multidisciplinary team in supporting patients across
the breadth of MS symptoms. He also discusses the valuable role of
self-monitoring for people with MS and why identifying patients’ levels of
motivation can aid healthcare professionals in identifying how best to provide
support. Finally, he shares his positive outlook for the future of SPMS care
and research.
101785 | UK | November 2020
Unmute
MS is a series of podcasts sponsored by Novartis Pharmaceuticals UK
investigating the biggest questions in MS through talking to a range of leading
experts across different sectors in the field. Dr
Wallace Brownlee, a MS Specialist Neurologist and MS Lead at the National Hospital for
Neurology and Neurosurgery joins us for the first of a two-part series to discuss the complexity
of defining SPMS and the limitations to the current diagnostic criteria. He
explores the ‘grey area’ when patients are transitioning between RRMS to SPMS
and the reasons underpinning clinicians’ reluctance to diagnose SPMS.
101442| UK | November 2020
Unmute MS is a series of podcasts
sponsored by Novartis Pharmaceuticals UK investigating the biggest questions
in MS through talking to a range of leading experts across different sectors
in the field. Dr David Rog, Consultant Neurologist at Salford Royal NHS
Foundation Trust delves into whether the sudden impact of COVID-19 provides a
once-in-a-generation opportunity to instigate change for the provision of
care for patients with MS. Dr Rog shares his first-hand experience of the
impact of the COVID-19 pandemic on clinical practice and how this may change
patient care in the future. He discusses the recent challenges and changes to
patient care and how in this complex environment, advances in technology and
a move towards personalised care and patient self-management could
revolutionise the approach to the health service in the UK.
101446 | UK | November 2020
Unmute MS is a series of podcasts
sponsored by Novartis Pharmaceuticals UK investigating the biggest questions
in MS through talking to a range of leading experts across different sectors
in the field. In this episode, Dr Agne Straukiene, a Consultant Neurologist at
Torbay and South Devon NHS Foundation Trust
explores the important role technology plays in MS management and shares her experience in
developing medical innovations to support the needs and management of
patients with MS. She discusses the power of technology as a tool to
transform patient care and predicts a new future in MS.
101441| UK | November 2020